Redirection of T-cell effector functions for cancer therapy: Bispecific antibodies and chimeric antigen receptors

Future Oncology

Volumn 9, Issue 4, 2013, Pages 527-539

  Satta, Alessandro ^a   Mezzanzanica, Delia ^a   Turatti, Fabio ^a   Canevari, Silvana ^a   Figini, Mariangela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

antibody engineering; bispecific antibodies; chimeric antigen receptors; clinical studies; single chain Fv; T cell effector function

Indexed keywords

AVIDIN; BISPECIFIC ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; CD28 ANTIGEN; CD3 ANTIGEN; ERTUMAXOMAB; GRANZYME B; LYMPHOCYTE ANTIGEN RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR;

ACCESSORY CELL; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ASCITES; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL ENGINEERING; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CELLS; CELLULAR IMMUNITY; CONTINUOUS INFUSION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DIMERIZATION; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; HEMATOLOGIC MALIGNANCY; HINGE REGION; HOST CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INTRACELLULAR SIGNALING; LYMPHOKINE ACTIVATED KILLER CELL; MALIGNANT ASCITES; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; RECOMBINANT DNA TECHNOLOGY; REVIEW; SOLID TUMOR; STEREOSPECIFICITY; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TRANSPOSON; UTERINE TUBE CARCINOMA;

ANTIBODIES, BISPECIFIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84875955851     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.203     Document Type: Review

References (124)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
2. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10(5), 301-316 (2010).
3. Carter PJ. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6(5), 343-357 (2006).
4. Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp. Cell Res. 317(9), 1261-1269 (2011).
5. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat. Rev. Cancer 12(4), 278- 287 (2012).
6. Reichert JM. Marketed therapeutic antibodies compendium. MAbs 4(3), 413-415 (2012).
7. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat. Rev. Clin. Oncol. 8(10), 577-585 (2011).
8. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281-298 (2011).
9. Steer HJ, Lake RA, Nowak AK, Robinson BW. Harnessing the immune response to treat cancer. Oncogene 29(48), 6301-6313 (2010).
10. Nisonoff A, Mandy WJ. Quantitative estimation of the hybridization of rabbit antibodies. Nature 194, 355-359 (1962).
11. Smith W, Jarrett AL, Beattie RE, Corvalan JRF. Immunoglobulins secreted by a hybrid-hybridoma: analysis of chain assemblies. Hybridoma 11, 87-98 (1992).
12. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9(7), 617-621 (1996). (Pubitemid 26241639)
13. Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25(11), 1290-1297 (2007). (Pubitemid 350076510)
14. Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J. Immunol. 163(3), 1246-1252 (1999). (Pubitemid 29352740)
15. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl Acad. Sci. USA 103(18), 6841-6846 (2006).
16. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs doi:10.4161/ mabs.4.2.19000 (2012) (Epub ahead of print).
17. van Spriel AB, van Ojik HH, van de Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol. Today 21(8), 391-397 (2000). (Pubitemid 30612300)
18. Kontermann RE. Alternative antibody formats. Curr. Opin. Mol. Ther. 12(2), 176-183 (2010).
19. Haagen IA, Geerars AJ, de Lau WB, Bast BJ, de Gast BC. The efficacy of CD3 × CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood 85(11), 3208-3212 (1995).
20. Kroesen BJ, Nieken J, Sleijfer DT, et al. Approaches to lung cancer treatment using the CD3 × EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol. Immunother. 45(3-4), 203-206 (1997). (Pubitemid 27521460)
21. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl Cancer Inst. 87, 1463-1469 (1995).
22. Nitta T, Sato K, Yagita H, Okumura K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335(8686), 368-371 (1990). (Pubitemid 20059349)
23. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 36(6), 458-467 (2010).
24. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol. Ther. 136(3), 334-342 (2012).
25. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29(11), 550-557 (2011).
26. Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant. Proc. 21, 127-130 (1989). (Pubitemid 19117939)
27. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86, 10024-10028 (1989). (Pubitemid 20030768)
28. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720-724 (1993). (Pubitemid 23028937)
29. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunother. 45(3-4), 131-136 (1997). (Pubitemid 27521442)
30. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk-Cbl association and Cbl phosphorylation. J. Biol. Chem. 272, 8551-8557 (1997). (Pubitemid 27147820)
31. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891-901 (1991). (Pubitemid 121001177)
32. Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J. Immunol. 160(1), 145-154 (1998). (Pubitemid 28116725)
33. Kruschinski A, Moosmann A, Poschke I, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl Acad. Sci. USA 105(45), 17481-17486 (2008).
34. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106(5), 1544-1551 (2005). (Pubitemid 41208564)
35. Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J. Immunol. 180(1), 72-78 (2008).
36. Turatti F, Figini M, Alberti P, Willemsen RA, Canevari S, Mezzanzanica D. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J. Gene Med. 7(2), 158-170 (2005). (Pubitemid 40348020)
37. Turatti F, Figini M, Balladore E, et al. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J. Immunother. 30(7), 684-693 (2007). (Pubitemid 47480752)
38. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J. Immunol. 173(12), 7647-7653 (2004). (Pubitemid 39628207)
39. Moritz D, Groner B. A spacer region between the single chain antibody-and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. 2(8), 539-546 (1995).
40. Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 5(9), 1195-1203 (1998). (Pubitemid 28448427)
41. Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther. 6(3), 412-419 (1999). (Pubitemid 29132343)
42. Kershaw MH, Darcy PK, Hulett MD, Hogarth PM, Trapani JA, Smyth MJ. Redirected cytotoxic effector function. Requirements for expression of chimeric single chain high affinity immunoglobulin E receptors. J. Biol. Chem. 271(35), 21214-21220 (1996). (Pubitemid 26292975)
43. Kershaw MH, Westwood JA, Parker LL, et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20 Pt 1), 6106-6115 (2006). (Pubitemid 44703776)
44. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173(12), 7125- 7130 (2004). (Pubitemid 39628146)
45. Hombach A, Sent D, Schneider C, et al. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res. 61(5), 1976-1982 (2001). (Pubitemid 32692016)
46. Beecham EJ, Ma Q, Ripley R, Junghans RP. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J. Immunother. 23(6), 631-642 (2000).
47. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20(1), 70-75 (2002). (Pubitemid 34044918)
48. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161(6), 2791-2797 (1998). (Pubitemid 28425698)
49. Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. 26(10), 2304-2309 (1996). (Pubitemid 26340928)
50. Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 167(11), 6123-6131 (2001). (Pubitemid 33081538)
51. Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119(3), 696-706 (2012).
52. Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71(13), 4617-4627 (2011).
53. Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72(7), 1844-1852 (2012).
54. Tammana S, Huang X, Wong M, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 21(1), 75-86 (2010).
55. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106(9), 3360-3365 (2009).
56. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 18(2), 413-420 (2010).
57. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18(4), 843-851 (2010).
58. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematological relapse-free survival in a Phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood 120(26), 5185-5187 (2012).
59. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119(26), 6226-6233 (2012).
60. Thakur A, Sorenson C, Norkina O, Schalk D, Ratanatharathorn V, Lum LG. Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants. Transfusion 52(1), 63-75 (2012).
61. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur. J. Immunol. 33(5), 1334-1340 (2003). (Pubitemid 36609151)
62. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16(9), 1245-1256 (2010).
63. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99(6), 2009-2016 (2002). (Pubitemid 34525482)
64. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23), 6050-6056 (2011).
65. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709-2720 (2012).
66. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18), 4817-4828 (2011).
67. Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 119(1), 72-82 (2012).
68. Di SA, De AB, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113(25), 6392-6402 (2009).
69. Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23(10), 1043-1053 (2012).
70. ClincalTrials.gov. A open label, dose escalating study to evaluate the safety and tolerability of ascending intravenous (i.v.) doses of catumaxomab in epithelial cancer patients (2012). http://clinicaltrials.gov/ct2/show/NCT01320 020?term=NCT01320020&rank=1
71. ClincalTrials.gov. Safety and efficacy study of catumaxomab to treat ovarian cancer after a complete response to chemotherapy (2012). http://clinicaltrials.gov/ct2/show/NCT00377 429?term=NCT00377429&rank=1
72. ClincalTrials.gov. Study of the trifunctional antibody catumaxomab to treat recurrent symptomatic malignant ascites (2011). http://clinicaltrials.gov/ ct2/show/NCT00326 885?term=NCT00326885&rank=1
73. ClinicalTrials.gov. Phase II study of the trifunctional antibody catumaxomab administered intra-and postoperatively in patients with ovarian cancer (2012). http://clinicaltrials.gov/ct2/show/NCT00563 836?term= NCT00563836&rank=1
74. ClinicalTrials.gov. Catumaxomab as a consolidation therapy in patients with ovarian cancer in second or third clinical disease remission (2010). http://clinicaltrials.gov/ct2/show/NCT01246 440?term=NCT01246440&rank=1
75. ClinicalTrials.gov. Randomized, multicenter, 2-dose level, open-label, Phase IIa study with the intraperitoneally infused trifunctional bispecific antibody Removab™ (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients (2006). http://clinicaltrials.gov/ct2/show/NCT00189 345?term=NCT00189345&rank=1
76. ClinicalTrials.gov. CASIMAS: catumaxomab safety Phase IIIb study with intraperitoneal infusion in patients with malignant ascites due to epithelial cancers (2012). http://clinicaltrials.gov/ct2/show/NCT0082 2809?term= NCT00822809&rank=1
77. ClinicalTrials.gov. Safety study of second intraperitoneal (I.P.) Infusion cycle of catumaxomab in patients with malignant ascites (SECIMAS) (2012). http://clinicaltrials.gov/ct2/show/NCT01065 246?term= NCT01065246&rank=1
78. ClinicalTrials.gov. Study in EpCAM positive patients with symptomatic malignant ascites using removab versus an untreated control group (2009). http://clinicaltrials.gov/ct2/show/NCT0083 6654?term=NCT00836654&rank=1
79. ClinicalTrials.gov. Safety and efficacy study with catumaxomab in patients after curative resection of a gastric adenocarcinoma (2007). http://clinicaltrials.gov/ct2/show/NCT00352 833?term=NCT00352833&rank=1
80. ClinicalTrials.gov. Phase II study with catumaxomab in patients with gastric cancer after neoadjuvant CTx and curative resection (2012). http://clinicaltrials.gov/ct2/show/NCT0046 4893?term=NCT00464893&rank=1
81. ClinicalTrials.gov. Catumaxomab for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas (CatuNeo) (2012). http://clinicaltrials.gov/ct2/show/NCT01504 256?term=NCT01504256&rank=1
82. ClinicalTrials.gov. Phase II study with the trifunctional antibody ertumaxomab to treat metastatic breast cancer progressing after endocrine treatment (2009). http://clinicaltrials.gov/ct2/show/NCT00452 140?term=NCT00452140&rank=1
83. ClinicalTrials.gov. Phase II study with the trifunctional antibody ertumaxomab to treat metastatic breast cancer after progression on trastuzumab therapy (2011). http://clinicaltrials.gov/ct2/show/NCT00522 457?term= NCT00522457&rank=1
84. ClinicalTrials.gov. Phase II study of the BiTE® blinatumomab (MT103) in patients with minimal residual disease of B-precursor acute ALL (2012). http://clinicaltrials.gov/ct2/show/NCT0056 0794?term=NCT00560794&rank=1
85. ClinicalTrials.gov. Study of the BiTE® blinatumomab (MT103) in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) (2012). http://clinicaltrials.gov/ct2/show/NCT01209 286?term= NCT01209286&rank=1
86. ClinicalTrials.gov. Confirmatory Phase II study of blinatumomab (MT103) in patients with minimal residual disease of B-precursor ALL (BLAST) (2012). http://clinicaltrials.gov/ct2/show/NCT01207 388?term=NCT01207388&rank=1
87. ClinicalTrials.gov. Clinical study with blinatumomab in pediatric and adolescent patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (2013). http://clinicaltrials.gov/ct2/show/NCT014717 82?term=NCT01471782&rank=1
88. ClinicalTrials.gov. Clinical study with blinatumomab in patients with relapsed/ refractory B-precursor acute lymphoblastic leukemia (ALL) (2013). http://clinicaltrials.gov/ct2/show/NCT014661 79?term=NCT01466179&rank=1
89. ClinicalTrials.gov. Safety study of the bispecific T-cell engager blinatumomab (MT103) in patients with relapsed NHL (2012). http:// clinicaltrials.gov/ct2/show/NCT002747 42?term=NCT00274742&rank=1
90. ClinicalTrials.gov. Phase I Study of MT110 in lung cancer (adenocarcinoma and small cell), gastric cancer or adenocarcinoma of the gastro-esophageal junction, colorectal cancer, breast cancer, hormone-refractory prostate cancer, and ovarian cancer (MT110-101) (2012). http://clinicaltrials.gov/ct2/show/ NCT00635 596?term=NCT00635596&rank=1
91. ClinicalTrials.gov. A study to evaluate the safety and tolerability of MEDI-565 in adults with gastrointestinal adenocarcinomas (2012). http://clinicaltrials.gov/ct2/show/NCT01284 231?term=NCT01284231&rank=1
92. ClinicalTrials.gov. Treated T cells followed by a stem cell transplant in treating patients with multiple myeloma (2012). http://clinicaltrials.gov/ct2/ show/NCT00938 626?term=NCT00938626&rank=1
93. ClinicalTrials.gov. Study of the trifunctional antibody FBTA05 and donor lymphocyte infusion in B-cell lymphoma after allogeneic stem cell transplantation (STP-LYM-01) (2012). http://clinicaltrials.gov/ct2/show/ NCT011385 79?term=NCT01138579&rank=1
94. ClinicalTrials.gov. Combination chemotherapy followed by autologous stem cell transplant, and white blood cell infusions in treating patients with non-Hodgkin's lymphoma (2012). http://clinicaltrials.gov/ct2/show/NCT00244 946?term=NCT00244946&rank=1
95. ClinicalTrials.gov. Laboratory-treated autologous lymphocytes, aldesleukin, and sargramostim (GM-CSF) in treating patients with advanced solid tumors (2012). http://clinicaltrials.gov/ct2/show/NCT010818 08?term= NCT01081808&rank=1
96. ClinicalTrials.gov. Anti-CD3 × anti-Erbitux® armed activated t cells (Phase Ib) for gastrointestinal (GI cancer) (2012). http://clinicaltrials. gov/ct2/show/NCT01420 874?term=NCT01420874&rank=1
97. ClinicalTrials.gov. Local treatment of metastatic melanoma with autologous lymphocytes and the bispecific antibody rM28 (2013). http://clinicaltrials.gov/ct2/show/NCT002 04594?term=NCT00204594&rank=1
98. ClinicalTrials.gov. Study to assess the tolerability of a bispecific targeted biologic IMCgp100 in malignant melanoma (2012). http://clinicaltrials. gov/ct2/show/NCT0121 1262?term=NCT01211262&rank=1
99. ClinicalTrials.gov. Genetically engineered lymphocyte therapy after peripheral blood stem cell transplant in treating patients with high-risk, intermediate-grade, B-cell non-Hodgkin lymphoma (2012). http://clinicaltrials. gov/ct2/show/NCT0131 8317?term=NCT01318317&rank=1
100. ClinicalTrials.gov. CD19-CAR immunotherapy for childhood acute lymphoblastic leukemia (ALL) (CD19TPALL) (2012). http://clinicaltrials.gov/ct2/ show/NCT0119 5480?term=NCT01195480&rank=1
101. ClinicalTrials.gov. Study of donor derived, multi-virus-specific, cytotoxic T-lymphocytes for relapsed/refractory neuroblastoma (STALLONe) (2011). http://clinicaltrials.gov/ct2/show/NCT0146 0901?term=NCT01460901&rank=1
102. ClinicalTrials.gov. Blood T-cells and EBV specific CTLs expressing GD-2 specific chimeric T cell receptors to neuroblastoma patients (NESTLES) (2012). http://clinicaltrials.gov/ct2/show/NCT000 85930?term=NCT00085930&rank=1
103. ClinicalTrials.gov. Trial of anti-PSMA designer T cells in advanced prostate cancer after non-myeloablative conditioning (2012). http://clinicaltrials.gov/ct2/show/NCT006 64196?term=NCT00664196&rank=1
104. ClinicalTrials.gov. T lymphocytes, chronic lymphocytic leukemia, B-cell lymphoma or multiple myeloma, CHARKALL (2012). http://clinicaltrials.gov/ct2/ show/NCT0088 1920?term=NCT00881920&rank=1
105. ClinicalTrials.gov. CD19 Chimeric receptor expressing T lymphocytes in B-cell non Hodgkin's lymphoma and chronic lymphocytic leukemia (CRETI-NH) (2013). http://clinicaltrials.gov/ct2/show/NCT0058 6391?term= NCT00586391&rank=1
106. ClinicalTrials.gov. Study of the T-cells or EBV specific CTLs for advanced B-cell non Hodgkin's lymphoma and chronic lymphocytic leukemia (ATECRAB) (2012). http://clinicaltrials.gov/ct2/show/NCT0070 9033?term=NCT00709033&rank=1
107. ClinicalTrials.gov. Genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is resistant or refractory to chemotherapy (2012). http://clinicaltrials.gov/ct2/show/NCT0102 9366?term=NCT01029366&rank=1
108. ClinicalTrials.gov. Phase I/II study of B cell malignancies using T cells expressing an anti-CD19 chimeric receptor: assessment of the impact of lymphocyte depletion prior to T cell transfer (2012). http://clinicaltrials.gov/ ct2/show/NCT009 24326?term=NCT00924326&rank=1
109. ClinicalTrials.gov. Administration of anti-CD19-chimeric-antigen- receptor-transduced T cells from the original transplant donor to patients with recurrent or persistent B-cell malignancies after allogeneic stem cell transplantation (2013). http://clinicaltrials.gov/ct2/show/NCT0108 7294?term=NCT01087294&rank=1
110. ClinicalTrials.gov. Anti-CD19 white blood cells for children and young adults with B cell leukemia or lymphoma (2013). http://clinicaltrials.gov/ct2/ show/NCT0159 3696?term=NCT01593696&rank=1
111. ClinicalTrials.gov. In vitro expanded allogeneic Epstein-Barr virus specific cytotoxic T-lymphocytes (EBV-CTLs) Genetically targeted to the B-cell specific antigen CD19 positive residual or relapsed acute lymphoblastic leukemia after allogeneic hematopoietic progenitor cell transplantation (2012). http://clinicaltrials.gov/ct2/show/NCT0143 0390?term=NCT01430390&rank=1
112. ClinicalTrials.gov. Precursor B cell acute lymphoblastic leukemia (B-ALL) treated with autologous T cells genetically targeted to the B cell specific antigen CD19 (2012). http://clinicaltrials.gov/ct2/show/NCT0104 4069?term=NCT01044069&rank=1
113. ClinicalTrials.gov. Treatment of Relapsed or chemotherapy refractory chronic lymphocytic leukemia or indolent B cell lymphoma using autologous T cells genetically targeted to the B cell specific antigen CD19 (2013). http://clinicaltrials.gov/ct2/show/NCT004 66531?term=NCT00466531&rank=1
114. ClinicalTrials.gov. Consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 in patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab (2013). http://clinicaltrials.gov/ct2/show/ NCT0141 6974?term=NCT01416974&rank=1
115. ClinicalTrials.gov. CD19 CAR T cells for B cell malignancies after allogeneic transplant (2012). http://clinicaltrials.gov/ct2/show/NCT01475 058?term=NCT01475058&rank=1
116. ClinicalTrials.gov. CTLs expressing CD19 chimeric receptors, CD19 positive malignancies post SCT, MULTIPRAT (2012). http://clinicaltrials.gov/ct2/ show/NCT0084 0853?term=NCT00840853&rank=1
117. ClinicalTrials.gov. Administration of T lymphocytes for Hodgkin's lymphoma and non-Hodgkin's lymphoma (CART CD30) (2012). http://clinicaltrials. gov/ct2/show/NCT01316 146?term=NCT01316146&rank=1
118. ClinicalTrials.gov. Her2 and TGFBeta CTLs in treatment of Her2 positive malignancy (HERCREEM) (2012). http://clinicaltrials.gov/ct2/show/NCT0088 9954?term=Her2+and+TGFBeta+CTLs+in+ Treatment+of+Her2+Positive+Malignancy+ %28HERCREEM%29&rank=1
119. ClinicalTrials.gov. CMV-specific cytotoxic T lymphocytes expressing CAR targeting HER2 in patients with GBM (HERT-GBM) (2012). http://clinicaltrials. gov/ct2/show/NCT01109 095?term=NCT01109095&rank=1
120. ClinicalTrials.gov. Adoptive transfer of autologous T cells targeted to prostate specific membrane antigen (PSMA) for the treatment of castrate metastatic prostate cancer (CMPC) (2012). http://clinicaltrials.gov/ct2/show/ NCT01140 373?term=NCT01140373&rank=1
121. ClinicalTrials.gov. Trial of 2nd generation anti-CEA designer T cells in metastatic breast cancer (2012). http://clinicaltrials.gov/ct2/show/NCT00673 829?term=NCT00673829&rank=1
122. ClinicalTrials.gov. Phase II/pilot study of 2nd generation anti-CEA designer T cells in adenocarcinomas (2012). http://clinicaltrials.gov/ct2/show/ NCT01723 306?term=NCT01723306&rank=1
123. ClinicalTrials.gov. White blood cells with anti-EGFR-III for malignant gliomas (2013). http://clinicaltrials.gov/ct2/show/NCT01454 596?term= NCT01454596&rank=1
124. ClinicalTrials.gov. Genetically engineered lymphocytes, cyclophosphamide, and aldesleukin in treating patients with relapsed or refractory mantle cell lymphoma or indolent B-cell non-Hodgkin lymphoma (2012). http://clinicaltrials. gov/ct2/show/NCT00621 452?term=NCT00621452&rank=1